Mutations in the Human Sterol Δ^7 -Reductase Gene at 11q12-13 Cause Smith-Lemli-Opitz Syndrome

Christopher A. Wassif,¹ Cheryl Maslen,^{2,3} Stivelia Kachilele-Linjewile,¹ Don Lin,³ Leesa M. Linck,⁴ William E. Connor,³ Robert D. Steiner,⁴ and Forbes D. Porter¹

¹Unit on Molecular Dysmorphology, Heritable Disorders Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda; and ²Medical Genetics and University Congenital Heart Research Center, ³Division of Endocrinology, Diabetes, and Clinical Nutrition, Department of Medicine, and ⁴Departments of Pediatrics and Molecular and Medical Genetics, Child Development and Rehabilitation Center, Doernbecher Children's Hospital, Oregon Health Sciences University, Portland

Summary

The Smith-Lemli-Opitz syndrome (SLOS; also known as "RSH syndrome" [MIM 270400]) is an autosomal recessive multiple malformation syndrome due to a defect in cholesterol biosynthesis. Children with SLOS have elevated serum 7-dehydrocholesterol (7-DHC) levels and typically have low serum cholesterol levels. On the basis of this biochemical abnormality, it has been proposed that mutations in the human sterol Δ^7 -reductase (7-DHC reductase; E.C.1.3.1.21) gene cause SLOS. However, one could also propose a defect in a gene that encodes a protein necessary for either the expression or normal function of sterol Δ^7 -reductase. We cloned cDNA encoding a human sterol Δ^7 -reductase (DHCR7) on the basis of its homology with the sterol Δ^7 -reductase from Arabidopsis thaliana, and we confirmed the enzymatic function of the human gene product by expression in SLOS fibroblasts. SLOS fibroblasts transfected with human sterol Δ^7 -reductase cDNA showed a significant reduction in 7-DHC levels, compared with those in SLOS fibroblasts transfected with the vector alone. Using radiation-hybrid mapping, we show that the DHCR7 gene is encoded at chromosome 11q12-13. To establish that defects in this gene cause SLOS, we sequenced cDNA clones from SLOS patients. In three unrelated patients we have identified four different mutant alleles. Our results demonstrate both that the cDNA that we have identified encodes the human sterol Δ^7 -reductase and that mutations in DHCR7 are responsible for at least some cases of SLOS.

Received March 23, 1998; accepted for publication May 11, 1998; electronically published May 29, 1998.

Address for correspondence and reprints: Dr. Forbes D. Porter, Heritable Disorders Branch, National Institute of Child Health and Human Development, National Institutes of Health, Building 10, Room 9S241, 10 Center Drive, Bethesda, MD 20892-1830. E-mail: fdporter@helix.nih.gov

Introduction

The Smith-Lemli-Opitz syndrome (SLOS; also known as "RSH syndrome" [MIM 270400]) was first described in 1964 by Smith et al. (1964). Children afflicted with this syndrome have dysmorphic facial features, mental retardation, hypotonia, poor growth, and variable structural anomalies of the heart, lungs, brain, gastrointestinal tract, limbs, genitalia, and kidneys (Smith et al. 1964; Gorlin et al. 1990). Elevated levels of 7-dehydrocholesterol (7-DHC) are characteristic of this disorder (Irons et al. 1993; Natowicz and Evans 1994; Tint et al. 1994; Kelley 1995). The SLOS phenotype can be variable. Both a "mild" (type I) and a "severe" (type II) form have been described (Bialer et al. 1987; Curry et al. 1987; Gorlin et al. 1990). It is thought that both types represent a spectrum of the same disorder. Children afflicted with either the type I form or the type II form have elevated levels of 7-DHC (Tint et al. 1995; Cunniff et al. 1997). In cholesterol biosynthesis, 7-DHC is converted to cholesterol by the enzyme sterol Δ^7 -reductase. This NADPH-dependent enzyme catalyzes the reduction of the Δ^7 -diene bond in 7-DHC, to form cholesterol. Liver microsomes from a SLOS homozygote have been shown to have reduced activity of this enzyme (Shefer et al. 1995). On the basis of observations of increased serum 7-DHC, decreased serum cholesterol levels, and deficient sterol Δ^7 -reductase activity, we and others have hypothesized that the genetic defect causing SLOS is in the gene encoding the sterol Δ^7 -reductase. However, theoretically, the genetic defect could also be either in a cofactor or transporter necessary for sterol Δ^7 -reductase activity or in a transcription factor necessary for efficient expression of this enzyme.

We report both the cloning of a cDNA that encodes the human sterol Δ^7 -reductase and the identification of mutant cDNAs in SLOS patients. Human sterol Δ^7 -reductase is homologous to a sterol Δ^7 -reductase from *Arabidopsis thaliana*, to fungal sterol Δ^{14} -reductases, to fungal sterol Δ^{24} -reductases, and to the β -lamin receptor family. The gene encoding sterol Δ^7 -reductase maps to

chromosome 11q12-13. We have identified four separate mutant alleles from three unrelated SLOS patients. In one patient, we have identified both mutant alleles, and another patient may be homozygous for the identified mutation. Two of the identified mutations are single-base insertions, and a third is a 134-bp insertion; these insertions introduce frameshifts. The fourth mutation is a 96-bp deletion. To our knowledge, these are the first reported mutations in SLOS, and identification of these mutant alleles establishes that mutations in the sterol Δ^7 reductase gene cause SLOS.

Subjects and Methods

Patients and Cell-Culture Methods

Institutional-review-board approval was obtained for this research, and informed consent was obtained for the skin biopsies. The A2SLO and B3SLO cell lines used in this study were obtained from patients who were clinically diagnosed with SLOS, by R.D.S. and F.D.P. Both patients had elevated serum 7-DHC levels and were severely affected (type II). Neither had a family history of consanguinity. One cell line (GM03044) was obtained from the National Institute of General Medical Sciences (NIGMS) Human Genetic Mutant Cell Repository. The available clinical description of this patient is limited; however, the presence of ambiguous genitalia and diagnosis at age 2 wk suggest a severe case of SLOS. Elevated 7-DHC levels have been found in this cell line. Control cell lines (GM05659C and GM03468A) were also obtained from the NIGMS Human Genetic Mutant Cell Repository. Skin fibroblasts were propagated in Dulbecco's minimal Eagle medium and 10% fetal bovine serum (37°C, 5% CO₂). Cholesterol-deficient conditions for growth were created with McCoy's media supplemented with 5% lipoprotein-deficient serum (35 mg protein/ml, <12 fg cholesterol/ml; PerImmune). SV40 transformation of SLOS fibroblasts was as described elsewhere (Lei et al. 1992). For expression studies of the sterol Δ^7 -reductase cDNA, the open reading frame of the DHCR7 gene was amplified by PCR (Clonetech Advantage-HF PCR kit) and was subcloned into pIRES1neo (Clonetech). SV40-transformed fibroblasts were transfected with Lipofectamine (Gibco BRL) according to the manufacturer's protocol. Initial selection of clones was done with 400 μ g G418/ml. Clones were subsequently maintained in 200 µg G418/ml.

Sterol Analysis of Cell Pellets

The cell pellets were frozen and thawed twice. Lipids were then extracted as described by Folch et al. (1957). After saponification and extraction, the TMS derivatives of the cell sterols were prepared and subjected to gasliquid–chromatography analysis (Lin et al. 1993). The gas-liquid chromatograph (Perkin-Elmer model 8500) was equipped with a 25-m \times 0.32-mm (inner diameter) CP-WAX-57 CB capillary column (Chrompath). The temperatures of the column, detector, and injection port were 210°C, 250°C, and 250°C, respectively. Helium was used as the carrier gas, and cholestane was used as an internal standard. Protein content of the samples was determined by the method of Lowry et al. (1951).

Cloning of the cDNA, and Mutation Analysis

A human EST (IMAGE Consortium Clone ID704713) was labeled with α ^{[32}P]-dCTP, by means of a Boehringer Mannheim High Prime DNA Labeling Kit. This probe was then used to screen a Human Liver 5'-Stretch cDNA library (Clontech). Multiple clones were isolated. Sequencing was performed both by means of Amersham T7 Sequenase version 2.0, with gene-specific primers, and by automated sequencing on a Pharmacia ALFexpress using Cy5-labeled M13 universal and reverse primers. For mutation analysis, reverse transcriptase-PCR (RT-PCR) (Titan One Tube RT-PCR System; Boehringer Mannheim) was used to amplify overlapping fragments of the coding sequence. The mRNA encoding the sterol Δ^7 -reductase was prepared from fibroblasts grown for 7 d in cholesterol-depleted media, by means of a Qiagen RNeasy Mini Kit. 5' PCR primers with XbaI ends (5'-AGTCTAGA-3') were as follows: HSP1 (5'-TCT AGA TGG CGT CAC CAA TGA C-3'), HSP3 (5'-CCC AGC TCT ATA CCT TGT GG-3'), HSP5 (5'-CTT GGC TAT GCC GTC TCC ACC-3'), HSP7 (5'-CCA TGT GAC CAA TGC CAT GG-3'), HSP9 (5'-ACC ACC AGA AGG ACC TGT TC-3'), and HSP11 (5'-TCA ACT ACG TCG GCG ACC TG-3'). 3' PCR primers with EcoRI ends (5'-CGGAATTC-3') were as follows: HSP2 (5'-ATG GCA AGA AGT CAG GGA GAG-3'), HSP4 (5'-CTG TGA AAT TGC AGT CTC TGG-3'), HSP6 (5'-CAT GGC AGA TGT CAA TGG TC-3'), HSP8 (5'-GTC ATC GAG TGC TCC TAC AC-3'), HSP10 (5'-TGT AGA AGT AGG GCA GCA GG-3'), and HSP12 (5'-CCT GGC AGG AAC ACG CTC TTG-3'). Primer pairs included HSP1/HSP2, HSP3/HSP4, HSP5/HSP6, HSP7/HSP8, HSP9/HSP10, HSP11/HSP12, HSP1/HSP8, HSP3/HSP8, and HSP7/HSP12. The reverse-transcriptase reaction was done at 50°C for 20 min, followed by 10 min at 55°C. The PCR-amplification conditions included an initial denaturation at 94°C for 2 min; denaturation between cycles, at 94°C for 30 s; annealing steps of 10 cycles at 60°C and 25 cycles at 62°C; and extension at 68°C, as recommended in the Titan RT-PCR protocol. The PCR products were then subcloned into either pCR2.1 (Invitrogen), by TA cloning, or pBlueScript SK (Stratagene). All mutations were confirmed in clones obtained from at least two independent RT-PCR reactions. Homology analysis was performed by means of BLAST computer-based analysis (Altschul et al. 1990, 1997). Protein sequences were aligned by means of the GCG Pileup program (Wisconsin Package version 9.1-UNIX).

Radiation-Hybrid Mapping

A GeneBridge 4 radiation hybrid-mapping panel (Research Genetics), which consists of 93 radiation-hybrid clones, was screened by PCR analysis using primers specific for the DHCR7 gene. The primer pair (5'-GCCTGG GCT CCT AAT ACAG-3' and 5'-CAA GAG CGT GTT CTG CCA GG-3') amplified the expected 286-bp fragment of the 3' UTR, without cross-amplification from the hamster recipient DNA. The reactions were performed under standard buffer conditions (Perkin Elmer Cetus) and with 25 μ g of hybrid DNA in a 10- μ l total volume. The amplification conditions consisted of an initial denaturation at 94°C for 5 min; followed by 35 cycles of denaturing at 94°C for 30 s, annealing at 60°C for 30 s, and extension at 72°C for 30 s; and a final extension at 72°C for 5 min. The final PCR products were separated and visualized on a 1% agarose/ethidium bromide gel and were scored for the presence or absence of the appropriate product. The results were confirmed in a separate set of reactions under identical conditions, with a second primer pair that amplifies a 167-bp fragment from the coding region (5'-CCC ATC GGC GGA TAT GTA GG-3' and 5'-TGC AGC TGT CCA CCC CGC AC-3'). The results were submitted to the server at the Whitehead/MIT Center for Genome Research, for analysis. The computed results were returned and showed placement of the DHCR7 gene relative to the framework markers on the radiation-hybrid map. The result was correlated with the chromosome genetic map, by identification of markers flanking the DHCR7 locus that were common to both maps. The cytogenetic position of the locus was then inferred from the genetic map, given the relative physical positions of the flanking markers.

Results

On the basis of the predicted amino acid sequence of an *A*. *thaliana* enzyme that encodes a sterol Δ^7 -reductase activity (Lecain et al. 1996), we cloned, by homology, a cDNA that encodes the human sterol Δ^7 -reductase. The predicted amino acid sequence of the plant enzyme was used to identify a human expressed sequence tag (EST) (AA282412, tonsillar B-lymphocytes; IMAGE Consortium clone ID704713) that had significant homology. We used this human EST to isolate longer cDNA clones from a human liver library. The longest cDNA clone that we isolated was 1,852 nucleotides in length and encoded a 417-amino-acid open reading frame (fig. 1). This cDNA clone is truncated at an internal XbaI re-

1 2 2																			
-133	tctaga	tgg¢	cgt	caco	caa	tga	cag	aac	cgca	atc	tca	agg	gca	gtg	ggg	ccg	tgc	ctg	gga
-73	ggtgga	ctgg	gtti	ttca	act	ggc	jag	cgt	cato	ctt	cct	act	gct	gtt	cgc	ccc	ctt	cat	cgt
-13	ctacta	ctto	cat	CAT	GC	TTG	rga	CCA	GTAC	CAG	CTG	CGC	CCT	GAC	CGG	ccc	TGT	GGT	GGA
				М	А	С	D	Q	Y	s	С	А	L	т	G	Ρ	v	v	D
47	CATCGT	CAC	CGG	ACA:	L C C	TCG	GCT	CTC	GGA	CAT	CTG	GGC	CAA	GAC	TCC	ACC	TAT	AAC	GAG
	ΙV	т	G	Н	А	R	Ŧ	S	D	I	<u>B</u>	А	ĸ	т	Ρ	P	Ξ	т	R
107	GAAAGC	CGC	CCA	GCT	CTA	TAC	CTT	GTG	GGT	CAC	CTT	CCA	GGT	GCT	TCT	GTA	CAC	GTC	TCI
	KA	А	Q	L	Y	Т	L	W	v	т	F	Q.	v	L	Ţ.	Y	т	s	Ŧ
167	CCCTGA	CTTC	CTG	CAC	FAA	GTT	TCT	ACC	CGG	CTA	CGT.	AGG	AGG	CAT	CCA	GGA	GGG	GGC	CGI
	E D	F	С	Н	к	F	L	P	g	Y	v	G	G	I	Q	<u>x.</u>	<u> </u>	A	Y.
227	GACTCC	TGC	AGG	GGT:	rgt	GAA	CAA	GTA	TCA	GAT	CAA	CGG	CCT	GCA	AGC	CTG	GCT	CCI	CAC
	T P	<u>A</u>	G	v	_v	N	ĸ	Ξ.	<u>Q</u>	I	<u>N</u>	G	Ŀ	Q	¥.	W	Ξ	L	Ξ
287	GCACCT	GCT	CTG	GTT:	rgc.	AAA	CGC	TCA	ICTO	CCT	GTC	CTG	GTT	CTC	GCC	CAC	CAT	CAT	CTI
	H.L	L	<u></u>	F	A	N	A	H	ىل مەمە	L	s	W	<u>.</u>	S	_ <u>P</u> _	T	I.	1	E.
34/	CGACAA	CTG	GAT	CCC	ACT	GCT	GTG	GTG	CGCC	CAA	CAT	CCT	TGG	CTA	TGC	CGT	CTC	CAC	CTI
	D N	W	1	P	ւ 	4	w	C	<u>.</u>	N	Ŧ	_ 	<u>.</u>	, Y	A		- S	T	E
407	CGCCAT	GGTC	JAA) ی) ی) ی ح	JTA	CTT	TT	CCC		JAG	UGO	CAG	AGA	CTG	CAA	ATT	CAC	AGG	CAP
462	A M	V	<u>K</u>	<u>_</u>	¥.	F CAM	E.	<u>.</u>	T	3	A	R	<u>p</u>	C	ĸ	F.	T	G	N
467	TTTCTT	TTAC		JTAC	JAT	GAT	- טטיט 	CAT	GAU	JTT.	TAA		TCG	T AD	CGG	GAA	GIG	GTI	TGP
F 0 7	r r	I	19	I. Commu	M	M	<u><u>u</u></u>	1		1	N	<u>×</u>	R	-		<u></u>	*	<u>.</u>	<u> </u>
527	CTTCAA	GCT0	arr S	UTTC E		TGG	909 n	CUU	- GGI	aAT) T	UGT UU	CGC	UTG Mar	GAU	CCT T	CAT		CU1	GIC
507	CTTTCCC	L L L C C		г соли	- 	CCN	- - -	P CCN		1	.v nom	CNC		T	ית תרכי	CCT		ці Пост	0
367	CIICGC	AGC	SAA S	-DAU	500	GGA	1 20	UCH	CAG	UU	1.01	GAC m		A DOL	CHI	GGT	τ	1700	N
617	CORCOR	R CCN			ር ሞ እ	- -	ມ ແມ່ນ	TCA	ວ ~ຫຫ/	רו. ∼יתייתיי	CTC.	C 7 7	CCA	NAC		СТ Л	- р ССт	CAA	GAC
041	V t	OCA.	30C) N	311	- W	10	T	D	- TIC	ТТ.	- 1 0-	M	ten te	- m	w	v	T.	unn K	- m
707	CATTGA	~¥ ~ 10 m/r	~ ~ T C		TGA		 Դ	cee.	CTC	TTA	CCT	aaa	CTG		പ്പ	CTC	лст	- - - - - - - - - - - - - -	ĉ
	TD	T	ĉ	W.	. 10.11	н	F	a	- W	v	т. Т.	G	w		n. D	c	v		. T.
767	GCCTTA	TCT	TTA	CAC	ĞСт	GCA	GGG	тĒт	GTA	TT.	GGT	GTA	CCA	ccc	CGT	GČA	GCT	GTC	CAC
	P Y	T.	Y	. T	T.	0	a	Ti	Y	Ľ.	v	Ŷ	H	P	v	0	Ľ	s	T
827	CCCGCA	CGC	CGT	GGG	CGT	сĉт	GCT	GCT	GGG	CCT	GGT	GGG	CTA	CTA	CAT	CTI	ccc	GGT	GGC
	PH	X	v	G	v	L	L	L	G	L	v	G	Y	T	I	F	R	v	A
887	CAACCA	CCA	GAA	GGA	CCT	GTT	CCG	CCG	CAC	GGA	TGG	GCG	CTG	CCT	CAT	CTC	റററ	CAG	GAA
	ŃН	0	ĸ	D	Ŧ		. 		-							~16			К
947	GCCCAA			<i>u</i>	L	T .	R	R	- T -	D	G	R	C	Ľ	I	W	G	R	
		GGT	CAT	CGA	GTG	T CTC	R CTA	R CAC	ATC	D CGC	G GA	R TGG	GCA	GAG	IGCA		G		GCI
	P K	GGT(V	CAT I	CGA(E	GTG C	CTC B	R CTA	R CAC T	ATC	D CGC A	GA D	R TGG	GCA	L GAG R	I GCA H		G CAG	CAA K	GC1
1007	<u>р</u> к GCTGGT	GGT V GTC	CAT <u>I</u> GGG	CGA E CTT	GTG C CTG	CTC B GGG	CTA Y CGT	R CAC T GGC	ATCO S CCG	D CGC A CCA	GA D CTT		GCA Q CTA	GAG R CGT	I GCA H CGG		CAG	CAA K GAI	
1007	PK GCTGGT	GGT V GTC 8	CAT I GGG	CGA E CTT F		CTC B GGG	R CTA X CGT V	R CAC T GGC	T ATCO S CCGO R	D CGC A CCA	GA D CTT	R TGG G CAA N		L GAG R CGT	I GCA H CGG G	CCA H CGA D	CAG E CCT L	CAA K GAI M	
1007 1067	K GCTGGT L V CAGCCT	GGT V GTC <u>8</u> GGC	GGG GGG CTA	CGA E CTT F CTG		GGG GGG GGC	R CTA CGT CGT V CTG	R CAC T GGC A TGG	ATC S CCG R CGG	D GC A CCA H CGG	GA D CTT	R TGG CAA N CCT			I GCA H CGG G CTA	CCA H CGA D CTI	CAG CAG E CCT L CTA	CAA K GAT M CAT	
1007 1067	K GCTGGT L V CAGCCI S L	GGTC GTC GTC GGC A	CAT GGG GGG CTA Y	CGA E CTT F CTG C	GTG C CTG CTG C C C C C C C C C C C C C	GGG GGG GGC A	CTA CGT CGT CTG CTG	R CAC T GGC A TGG G	ATC S CCG R CGG G	D GGC A CCA H CGG G	GA D CTT F CCA H	R TGG CAA N CCT L		GAG R CGT CGT GCC P	I GCA H CGG G CTA	CCA H CGA D CTI	CAG E CCT L CTA	CAA K GAT M CAT I	
1007 1067 1127	E K GCTGGT L V CAGCCI S L CTACAI	GGTC V GTC B GGC A GGC	CAT GGG GGG CTA Y CAT	CGA E CTT E CTG C CCT	GIG C C C C C C C C C C C C C C C C C C		CTA CGT CGT CTG CTG CCA	R CAC T GGC T G G CCG	ATC S CCG CCG CGG CGG CTG	D CGC A CCA CCA G CGG G CCT	GA D CTT F CCA H CCG	R TGG CAA N CCT L GGA			I GCA H CGG G CTA CCG	CCA H CGA D CTI	CAG E CCT L CTA Y CGC	GAI GAI CAI CAI	
1007 1067 1127	E K GCTGGT L V CAGCCI S L CTACAT Y M	GGTC V GTC S GGC A GGC A	CAT GGG CTA Y CAT I	CGA E CTT CTG CTG C CCT L	GIG CTG CCT CCT L SCT	GGG GGG GGC A GAC T	CTA CGT CTG CTG CCA H	R CAC T GGC TGG G CCG R	ATC S CCG CGG CGG CGG CTG CTG	D GGC A CCA CGG G G CCT L	GA D CTT CCA H CCG R	R TGG CAA N CCT L GGA	GCA Q CTA GCT GCT L CGA E	GAG R CGT GCC P GCC P GCA H	I GCA H CGG G CTA CCG	CCA H CGA D CTI	CAG E CCT CTA CTA CGC A	GAI GAI M CAI I CAC	
1007 1067 1127 1187	E K GCTGGT L V CAGCCI S L CTACAI Y M GTACGG		CAT GGG CTA CTA Y CAT I GGA	CGA E CTT CTG CTG CCT CCT	GTG CTG CTG CCT L GCT GCT	GGG GGG GGC A GAC T GCG	CTA CGT CTG CTG CCA H CTA	R CAC T GGC TGG G CCG R CCG R CAC	ATC S CCG CGG CGG CTG CTG CCC	D GCCA CCA G G CCT L CGC	GA D CTT CCA H CCG AGT	R TGG CAA CCT L GGA GCC	GCA Q CTA GCT GCT GCT CGA E TTA	GAG R CGT GCC P GCA H CCG	I GCA H CGG G CTA CCG CCT	CCA CCA D CTI CTI CTI	CAG CCT L CTA CCTA CGC A GCC	R CAA GAI M CAI I CAC S TGC	
1007 1067 1127 1187	E K GCTGGI L V CAGCCI S L CTACAI Y M GTACGG	GGTC V GTC GGC A GGC A GGC A CCG R	CAT GGG CTA CTA Y CAT I GGA D		GTG CTG CTG CCT L GCT GCT GCT GGA	GGG GGG GGC A GAC T GCG R		R GGC TGG G CCG R CCG T CAC	ATCO S CCGO CGGO CGGO CTGO CGCO A	D GCA CCA G CGG G CCT L CGC A	GA D CTT CCA H CCG R AGT V	R TGG CAA CCT L GGA GCC P	GCA Q CTA GCT GCT CGA CGA TTA		I GCA H CGG G CTA CCG CCT L	CCA H CGA D CTI CTC CTC GCI L		CAA K GAI M CAI I CAC S TGC	
1007 1067 1127 1187 1247	P K GCTGGT L V CAGCCI S L CTACAT Y M GTACGG X G CTTCTA F *		CAT GGG CTA CTA Y CAT I GGA GGA		GTG CTG CTG CTT GCT GCT GGA CT GGA CT	GGG GGG GGC A GAC T GCG R agg		R CAC GGC TGG G CCG R CAC T aag	ATCO S CCG CGG CGG CTG CTG CGC A CGC	D GGC A CCA G G CCT L CGC A tgt	GA D CTT CCA H CCG R AGT V 9999	R TGG CAA CCT L GGA GCC P gct	GCA GCTA GCT GCT CGA CGA TTA gtc	GCC R CGT GCC P GCC P GCA H CCG R CCG	I GCA H CGG G CTA CCG CCT CCT L agc	CCA H CGA D CTI CTC GCI GCI GCI gtg	CAG CCTA CTA CTA CGC A GCC tto	R GAI GAI CAI I CAC S TGC tgc	
1007 1067 1127 1187 1247 1307	E K GCTGGT L V CAGCCI S L CTACAI Y M GTACGG Y G CTTCTA F * dtccaf		CAT GGG CTA CTA CAT GGA GGA gca		GTG CTG CTG CCT L GCT GGA CCT CCT CCT CCT CCT CCT CCT	GGG GGG GGC A GAC T GCG R agg		R GGC TGG G CCG R CCG R CAC T aag	ATCO S CCG CGG CGG CGG CGG CGC CGC CGC CGC	D GGC A CCA G G CCT L CGC A tgt	GA D CTT CCA H CCG H CCG AGT V 999	R TGG CAA CCAA CCT L GGA D GCC P gct	CTA CTA CTA GCI E CGA E TTA gtc ctc	GCC R CGT GCC P GCC P GCC H CCC R C CCC R CCC R C CCC C CCC R C CCC R C C CCC C C C C C C C C C C C C C C C C	I GCA G CGG CTA CCG CCT L CCT L CCT	CCA H CGA D CTI CTI GCI GCI L gtg	CAG CAG CCT L CTA CCTA A GCC P ttc	R GAI GAI M CAI I CAC S TGC TGC tgc	
1007 1067 1127 1187 1247 1307 1367	E K GCTGGT L V CAGCCI S L CTACAI Y M GTACGG Y G CTTCTA F * gtccat		CAT GGG CTA CAT CAT GGA gCa gCa		GTG CTG CTG CTG CCT L CCT L GCT L GGA CCT L CCT L CCT L CCT C CCT C CCT C CCT C CCT C CCT C CCT C CCT C CCT C	GGG GGG GGC GGC GGC GGC A GGC R GCG R agg CCC CCC CCC CCC CCC CCC CCC CCC CCC	CTA CGT CTG CTG CCA H CTA Y gag gag	R CAC T GGC T G G CCG R CCG R CAC T aag tcc		D CGC A CCA CGG G CCT L CGC A tgt tcg	G CGA D CTT F CCA H CCG R AGT V gggg aggg	R TGG CAA CCT L GGA GCC P gct agc	CCTA CCTA CCTA CCTA CCTA CCTA CCCA CCCA	GAG R CGT GCC P GCA H CCG R aagt aagt	I GCA H CGG G CTA CCG CCT A CCG A CCT A CCT A CCT A CCT A CCT A CCT A CCT A CCTA	CCA H CGA D CTI CCG CC CCG CCG CCG CCG CCG CCG CCG CCG	CAG ECCT L CTA CCT CCT CCTA CCTA CCTA CCTA CC	R K GAI CAI I CAG S CAG CAG tgc tgc	
1007 1067 1127 1187 1247 1307 1367 1427	E K GCTGGI L V CAGCCI S L CTACAI Y M GTACGG Y G CTTCTA F * gtccat ctggag ttgcct	GGTC V GTC: GGCC A GGCC A GGCC A CCG C A GGCC A CCG C C A GGCC A CCG C C C C	CAT <u>G</u> GG CTA CTA CAT GGA D gca ggc ggc aggc		GTG CTG CTG CTG CCT L GGA E CCT CCT L CCT CCT CCT CCT CCT CCT CCT C	GGGG GGCG A GACC T GCG R aggg cccc ttg	CTA CGT CCTG CCA H CTA gag gag agca agca	R CAC GGC TGG G CCG R CAC T aag tcc ggt	T ATCG S CCGG CCGG CCGG CCGG CCGG CCGG CCGG	D CGC A CCA CGG G CCT L CGC A tgt tcg cag	G CGA D CTT F CCA H CCG A GGG V gggg aggg tac	R TGG CCAA CCT L GGA D GCC P gct agc cta gta	CCTA GCA GCTA GCTA E CCFA CCFA TTA gtc ctc atc	GAG R CGT GCC P GCCA H CCCG R aagt aagt	I GCA H CGG G CTA CCG E CCT L CCG L CCT L CCT L CCG CCT L CCG CCT L CCG CCT CCG CCT CCG CCA CCG CCA CCG CCA CCGG CCA CCCG CCC CCC	CCA H CGAA D CTI CTG GCI GCI GCI GCI GCI CTG CTG CTG	CAG ECTA CCTA CCTA CCTA CCTA CCCC A GCCC ECCC A GCCC A CCCC A CCCC A CCCCA CCCTA CCCCA CCCTA CCCCA CCCTA CCCCCC	R GAT GAT M CAT I CAG S TGG tgc tgt ttg	
1007 1067 1127 1187 1247 1307 1367 1427 1487	E K GCTGGT L V CAGCCT S L CTACAT Y M GTACGG <u>Y</u> G CTTCTA F * gtccat ctggag ttgcct		CAT GGG CTA CTA CAT I GGA D gca gcc agg ccagg	CGA E CTTC CTGC CCTC CCTC CTGC CTGC CTGC CT	GTG CTG CTG CTG CTG CTG CTG CTG CTG CTG	GGGC GGCC A GAC T GCCG R agg cccc ttg cga agg	CTA CGT CGT CCTG CCA H CCA H CCA Gag gag gca gca gca gca	R CAC T GGC T GGC CCG R CCCG R CAC T aag tcc ggt tcc	ATC S CCG CCG CCG CCG CCG CCG CCG CCG CCG	D CGC A CCA CGG G CCT L CGC A tgt tcg cag act	GA CGA D CTT CCA H CCG AGT V gggg aggg tac cca	R TGG CCAA CCTT L GGA D GCCC P gct agcc cta gta gta	CCTA CCTA CCTA CCTA CCTA CCGA	GAG R CGI GCC P GCCA H CCG R aagt aagt acg	I GCA H CGG G CTA CCG R CCT L C C C C	CCA H CGAA D CTI CTG CC CC CC CC CC CC CC CC CC CC CC CC CC	CAG ECTA CTA CTA CCTA CCC A CCCC A CCC A CCC A CCC A CCC A CCC A CCC A CCCCC A CCCC A CCCC A CCCCC A CCCCC A CCCCCC	R GAI GAI CAI I CAG S CAG CAG CAG CAG CAG CAG CAG CAG CAG CAG	
1007 1067 1127 1187 1247 1307 1367 1427 1487 1547	E K GCTGGT L V CAGCCT S L CTACAT Y M GTACGG Y G CTTCTA F * gtccat ctggag ttgcct ctctaa acaatt	GGTC V GTC GGC GGC A GGC A GGC A CCG A CCG A CCG CG CG CG CG CG CG CG CG CG CG CG CG	CAT GGGG CTA CAT I GGA gca gcc gcc gcc gcc gcc gcc gcc gcc gcc	CGA(ECTTC CTG CCTG CCTG CCTG CCTG CCTG CCTG	GTG CTG CTG GCT GCT GCT GGA E c at c c c c	GGGC GGCC A GAC T GCG R agg ccc ttg cga ggg gag	CTA CGT CGT CCTG CCA H CCTA gag gag gca gca gca gca gca gca gca	R CAC GGC TGG G CCG R CCCG R CAC T aagg tcc ggt tcc gag	T ATCO S CCGG CCGG CCGG CCGG CCGG CCGG CCGG	D CGC A CCA CGG G CCT L CGC A tgt tcg cag act gac	GA D CTT CCA H CCG AGT V gggg aggg tac gcca tac	R TGG G CAA CCT L GGA GGC P gct agcc agca gta gtc act	GCA GCA GCTA GCTA GCTA GCTA GCTA GCTA GC	LGAG RCGT GCC PGCA HCCG RCCG RCCG RCCG RCCG RCCG RCCG RCCG	I GCAA H CGGG G CTA CCG CCG CCTA CCG CCTA L CCG A CCTA L CCG A CCTA L CCG A CCTA L CCG A CCTA L CCGG A CCTA L CCGG A CCAA A CCGG A CCAA A CCGG G CAA H CCGG G CAA A CCGG G CAA CCGG G CAA CCGG G CCAA CCGG G CCAA CCGG C CCAA CCGG C CCAA CCCG C CCAA CCCG C CCAA CCCG C CCAA CCCG C CCAA CCCG C CCAA CCCG C CCCA C CCCG C CCCA C CCCG C C CCCG C C CCCG C C CCCG C CCCG C C C C C C CCCG C C CCCG C	CCA H CCA CTI CTG GCTI L GCTI L GCTI C C C C C C C C C C C C C C C C C C	CAG CAG CTA CCTA CCTA CGC A CGC A CGC A CGC A CGC A CGC A CGC CTA	R GAI GAI CAI I CAG S CAG TGG tgc tgc tgc tgc tgc tgc	
1007 1067 1127 1187 1247 1307 1367 1427 1487 1547 1607	E K GCTGGT L V CAGCCT S L CTACAT Y M GTACGC Y G CTTCTA F * tctggag ttgcct ctctaa acatt	GGTC V GTCC GGCC A GGCC A GGCC A CCCG A CCCCG A CCCCG A CCCCG A CCCCG A CCCCG A CCCCG A CCCCG A CCCCG A CCCCG A CCCCG A CCCCG A CCCCCCCG A CCCCCCCC	CAT GGG GGG CTA Y CAT I GGA D gca ggcc ggcc ggcc gca gca cac	CGA(ECTT(CTG(CTG(CCTG) CCTG) CCTG(CCTG) CCTG) CCTG(CCTG) CCTG) CCTG(CCTG) CCTG) CCTG) CCTG CCTG) CCTG CCTG) CCTG CCTG	GTG CTG CTG GCT GCT CTT GCT CTT GCT CTT CT	GGG GGG GGC A GAC T GCG R agg GCG R agg GCG C C C C C C C C C C C C C C C C C	CTA CTA CGT CGT CCA CCA CCA CCA CCA CCA CCA CCA CCA CC	R CAC GGC TGG G CCGG R CAC CCG R CAC T aagg tcc ggt tcc gagg	T ATCC CGG CGG CGG CCGC CGCC A CCGC A CCGC A CCGC A CCGC A CCGC A CCGC A CCGC A CCGC A CCGC A CCGC A CCGC A CCGC A CCGCC CCGC CCCGC CCGC	D CGC A CCA CGG G CCT L CGC A tgt tcg caga caga caga	GACCGA D CTTT CCCA H CCCG AGT V gggg aggg taccca cca cca tac	R TGG G CAAA CCT L GGA GCC P gct agca gta gta acta	GCA GCA GCTA GCTA GCTA GCTA GCTA GCTA GC	LGAG RCGT GCC PGCA HCCG RCCG RCCG CCG CCG CCG CCG CCG CCG CC	I GCAA H CGGG G CTA CCGG CCTA L CCGG CCT L CCGG CCT L CCGG CCTA L CCGG CCTA L CCGG CCTA L CCGG CCTA	CCA H CGA D CTI CTC GCI L GCI L gtg ctct ctgt cagt aaa	CAG ECTA CCTA CCTA CCTA CCTA CCCC A CCCC A CCCC A CCCC A CCCC A CCCC A CCCC A CCCC A CCCC A CCCC A CCCC A CCCC A CCCC CAG A CCCC CAG A CCCC CCTA CCCC CCTA CCCC CCTA CCCC CCTA CCCC CCTA CCCCCA CCCCCA CCCA CCCA CCCCA CCCA CCCCA CCCCA CCCCA CCCA CCCA CCCA CCCA CCCCA CCCCA CCCA CCCA CCCCA CCCCA CC	R GAA K GAT I C I C I C I C I C I C I C I C I C I	
1007 1067 1127 1187 1247 1307 1367 1427 1487 1547 1607	E K GCTGGT L V CAGCCI S L CTACAT Y M GTACGC Y G CTTCTA F * gtccat ctggag ttgcct ctctaa acaatt aggtt gggag	GGTC V GTCC GGCC A GGCC A GGCC A CCGG A CCGG (A A GGCC A CCGG (A CCGG (A CCGG) (A CCGG) (A CCGG) (A CCGG) (A CCGC) (A CCC) (CCC) (A CCC) (A CCC) (CCC) (A CCC) (CCCC) (CCC) (CCC) (CCC) (CCC) (CCC) (CCCC) (CCCC) (CCCC	CAT GGG CTA CAT CAT GGA gcc gcc gcc gcc gcc gcc gcc gcc gcc gc	CGA(E CTTC CTG CCTG CCTG CCTG CCTG CCTG CCT	GTG CTG CTG CTG CTG CTG CTG CTG CTG CTG	GGG GGC GGC A GGAC T GCG R agg GGC C C GCG R agg G ggg gag a aaa	CTA CTA CGT CGT CCA CCA CCA CCA CCA CCA CCA CCA CCA CC	R CAC GGC TGG G CCGG R CAC CAC T aag tcc ggt tcc gag agg aaa	T ATC CGG CGG CGG CGG CGG CGG CGG CGG CGG C	D CGC A CCA CGG CCT L CGC A tgt tcgg act cag act cag act	GACCGA DCTT CCA HCCG AGT V gggg aggg tacc cca taca	R TGG CAA CCT L GGA GCC P gct agc cta gtc acta agt cta	GCA GCTA GCTA GCT GCTA CGA CGA TTA gtc ctc actg actg cactg	LGAG RCGT GCC PGCA HCCG CGC CCC CGC CGC CGC CGC CGC CGC CG	I GCA H CGG G CTA CCA CCA CCA CCA CCA CCA CCA CCA CCA	CCA H CGA D CTI CTC CCC CCC CCCC CCCC CCCCCCCCCCC	CAG CAG CCT CTA CCTA CCTA CCTA CCCC CCTA CCCC CCTA CCCC CCTA CCCC CCTA CCCC CCTA CCCC CCTA CCCC CCTA CCCC CCTA CCCC CCTA CCCC CCTA CCCC CCTA CCCC CCTA CCCC CCTA C	R GAI GAI CAI I CAC S C CAC S C CAC S C C CAC S C C C C	

Figure 1 Nucleotide and amino acid sequence of clone pH7DHCR encoding the human sterol Δ^7 -reductase. Amino acids that are identical between the human cDNA and the A. thaliana cDNA are underlined and are in boldface type. Amino acids that are similar are gray shaded (BLASTP 2.0.4). A putative polyadenylation signal in the 3' UTR is underlined.

striction site. Thus, the mRNA potentially encodes a longer peptide. At the amino acid level, the predicted protein has 37% identity and 55% similarity (BLASTP 2.0.4; Altschul et al. 1997) to the A. thaliana enzyme. Although the highest sequence homology was found with the functionally similar A. *thaliana* sterol Δ^7 -reductase, the predicted peptide also has significant homology to fungal sterol Δ^{14} -reductases (GenBank accession numbers Y10624, S30769, S44170, and X94315), to the carboxyl-terminal portions of the human and rat β -lamin receptors (GenBank accession numbers L25941 and AB002466), and to fungal sterol Δ^{24} -reductases (GenBank accession numbers S64014 and A43765) (fig. 1, and data not shown). Neither the human nor the plant sterol Δ^7 -reductase has the EFGGXXG motif conserved in the sterol Δ^{14} -reductases, in the sterol Δ^{24} -reductases, and in the β -lamin receptors (Lecain et al. 1996). Thus, on the basis of homology, this gene likely encodes the human sterol Δ^7 -reductase. While the manuscript of this article was in preparation, Moebius et al. (1998) reported an independent cloning of this gene. They showed the presence of sterol Δ^7 -reductase activity when this gene was expressed in *Saccharomyces cerevisiae*. Mutational analysis in SLOS was not reported. This work provides further conformation that this cDNA that we identified encodes human sterol Δ^7 -reductase.

Cholesterol biosynthesis in cells is highly regulated, and transcription of cholesterol biosynthetic enzymes is down-regulated when exogenous LDL cholesterol is available. Using northern blot analysis, we compared the expression of the human sterol Δ^7 -reductase in fibroblasts grown with and without an exogenous source of LDL cholesterol. Consistent with an enzyme involved in cholesterol biosynthesis, the mRNA encoding this protein is induced when fibroblasts are grown in LDL cholesterol–deficient media (fig. 2). No marked differences were observed between control lines and SLOS lines (fig. 2, and data not shown).

To prove that this cDNA encodes a sterol Δ^7 -reductase, we cloned this cDNA into an expression vector, pIRES1neo, and stably transfected this construct into two SV40-transformed SLOS fibroblast lines (A2SLO-T and B3SLO-T). This vector (pIRES1neo8) constitutively expresses the putative sterol Δ^7 -reductase cDNA, under control of the human cytomegalovirus major, immediate, early promotor/enhancer. Using gas chromatography, we measured sterol levels in cell lines expressing the sterol Δ^7 -reductase cDNA, and we compared these levels with levels of 7-DHC in cell lines transfected with the vector alone. After 5 d of growth in lipoprotein-deficient serum, cholesterol levels increased to 166% of control levels, and 7-DHC levels decreased to 45% of control levels (table 1). The 7-DHC/cholesterol and 7-DHC/totalsterol ratios were decreased, respectively, to 26% and 38% of control levels. In a similar experiment, with the B3SLO cell line, the 7-DHC/cholesterol and 7-DHC/total-sterol ratios were decreased, respectively, to 52% and 65% of control levels (P < .005). The variability between cell lines is likely due to the use of pools of transfected cells. These results prove that the human cDNA isolated by homology to the A. *thaliana* Δ^7 -reductase functionally encodes a sterol Δ^7 -reductase.

We used radiation-hybrid mapping to learn the chromosomal location of the human sterol Δ^7 -reductase gene. The data vector resulting from screening the radiationmapping panel was 10010 00001 00000 10011 00000 00110 00000 10001 01001 10000 00100 00000 01001 00011 00110 00001 11001 00000 001. Interpretation of these data from the radiation-hybrid map placed the *DHCR7* gene 2.33 cR₃₀₀₀ from GCT16B07 on chromosome 11, linking it, at a LOD score of 19, with



Figure 2 Northern blot analysis comparing expression of the human sterol Δ^7 -reductase mRNA from fibroblasts grown with fetal bovine serum (+), compared with fibroblasts grown in lipoprotein-deficient serum (-). A 7.5- μ g sample of total RNA was loaded in each lane. The *DHCR7* transcript is ~4 kb. Equivalent loading of samples was confirmed by means of a probe to human *GADPH* (data not shown).

D11S913 and D11S916. The position of *DHCR7* relative to both the radiation-hybrid map and the corresponding genetic and cytogenetic maps is shown in figure 3. Given its position between D11S913 and D11S916 on the radiation-hybrid map, *DHCR7* can be assigned a placement 70.9–80.1 cM from the top of the genetic map of chromosome 11. Cytogenetically, it is therefore likely that the *DHCR7* locus is in the 11q12-13 interval.

To determine whether mutations in the human sterol Δ^7 -reductase gene cause SLOS, we used RT-PCR to subclone overlapping segments of cDNA from SLOS fibroblasts. Sequence analysis of these cDNAs allowed us to identify four mutations in three unrelated patients (table 2). A 134-bp insertion (figs. 1 [nucleotide 788/789] and 4A) was identified in the A2SLO cell line. This insertion results in a frameshift, starting at amino acid 263, that precludes translation of the highly conserved carboxyl end of the protein. This cell line may be homozygous for this insertion. Of seven cDNA clones sequenced from this region, all had the 134-bp insertion (P < .01). Northern blot analysis showed the presence of a slightly larger transcript in mRNA from the A2SLO cell line (fig. 4B). Finally, PCR analysis of this region demonstrated the presence of a single larger product in A2SLO samples (fig. 4C). A normal-size allele was not observed. Four separate primer pairs (HSP3/HSP8, HSP5/HSP8, HSP7/ HSP8, and HSP7/HSP10) that flank this region gave similar results (data not shown). Thus, our sequencing, northern blot, and PCR data are consistent with the presence of a homozygous mutant allele. Alternatively, a second allele could be untranscribed or could give rise to an unstable transcript that is not detectable by either RT-PCR or northern blot analysis.

Both mutant alleles were identified in a second SLOS patient (B3SLO). One mutation is a 96-bp deletion (fig. 1, nucleotides -77 to 19). This mutation potentially removes the start codon. Neither of the two ATGs present in the undeleted 5' region are in-frame, and the next in-frame ATG encodes amino acid 138. If the initiation codon is 5' of the XbaI site, then this mutation would result in both the removal of 32 amino acids from the amino terminus of this enzyme and introduction of a cysteine residue. Consistent with the autosomal recessive nature of this disorder, this patient has a second mutant allele. The second allele has a single cytosine insertion between nucleotides 505 and 506. This insertion results in both a frameshift starting at amino acid 170 and addition of 39 aberrant amino acids.

A fourth mutation was also identified in the C4SLO cell line. This mutation is a single thymidine insertion between nucleotides 586 and 587. The result of this insertion is both a frameshift starting at amino acid 197 and the addition of 12 aberrant amino acids. We have not yet identified the second mutation in this cell line. Both the single-base insertions in B3SLO and C4SLO would preclude normal translation of the highly conserved carboxyl-terminal half of this protein.

Discussion

The human sterol Δ^7 -reductase catalyzes the reduction of the Δ^7 -diene bond in 7-DHC, to form cholesterol. Children with SLOS have elevated serum levels of 7-DHC and often have low serum cholesterol levels, and cells from these patients have decreased sterol Δ^7 -reductase activity. On the basis of these observations, it had been proposed that SLOS is the result of a defect in cholesterol biosynthesis. A defect in cholesterol biosynthesis can readily explain the low cholesterol levels and

Table 1

Sterol Analy	ysis in A2SLC) Fibroblasts	Expressing	Human	Sterol Δ^7	'-Reductase	cDNA
--------------	---------------	---------------	------------	-------	-------------------	-------------	------



NOTE.—Stably transfected cell lines were grown for 5 d in lipoprotein-deficient media. Sterol analysis of the cell pellets was done by gas chromatography.

^a Of three samples.

^b P < .02, by Student's paired *t*-test.



Figure 3 DHCR7 locus integrated into the radiation-hybrid map of human chromosome 11, with correlation to the genetic and cytogenetic maps. Numbers to the right of the radiation hybrid and genetic maps indicate distances from the top of the maps, in cR_{3000} and cM, respectively. The inferred position of the DHCR7 gene at 11q12-13 is indicated by the bar to the left of the ideogram.

high 7-DHC levels in blood and tissues, abnormal bile acid profiles, hepatic failure, growth failure, genital hypoplasia, and hypomyelination seen in this disorder. The relationship between a defect in cholesterol biosynthesis and the developmental malformations that also characterize this disorder was initially more difficult to explain. However, it is now known that sonic hedgehog (shh), a morphogen involved in patterning the CNS and limbs, is anchored to the plasma membrane via a covalent bond with cholesterol (Porter et al. 1996a, 1996b). Thus, shh function may be impaired in SLOS, because of either cholesterol deficiency or the presence

 Table 2

 Mutations of Human Sterol H⁷-Reductase, Identified in SLOS

Patient	SLO Type	Mutation	Nucleotide Position
A2SLO	II	134-bp insertion	788/789
B3SLO	II	C insertion	507/508 -77 to 19
C4SLO	\prod^a	T insertion	587/588

^a Available clinical description is limited.

of high levels of 7-DHC. Consistent with this idea, the shh-mutant mouse has phenotypic overlap with severe SLOS (Chiang et al. 1996). In addition, pharmacological inhibitors of sterol Δ^7 -reductase are teratogenic, and rat embryos exposed to these inhibitors have phenotypic overlap with both severe SLOS and the shh-mutant mouse (Roux et al. 1980; Dehart et al. 1997).

Given the observed biochemical defect of deficient sterol Δ^7 -reductase activity, we and others had hypothesized that the genetic defect would be in the gene encoding this enzyme. However, it was also possible that the genetic defect could be in a cofactor of this enzyme, a transporter necessary for sterol Δ^7 -reductase activity, or in a transcription factor necessary for normal expression of this enzyme. To answer this question, we have cloned a cDNA encoding a human sterol Δ^7 -reductase. This cDNA encodes a 417-amino-acid open reading frame. Our cDNA is truncated at an internal *XbaI* site. Thus, it is possible that the mRNA encodes a longer peptide. A longer open reading frame, of 475 amino acids, has been reported by Moebius et al. (1998). The plant sterol Δ^7 -reductase has an open reading frame of 430 amino acids; and the homology between the plant and human genes is poor in this area. However, the amino terminus predicted by the previous clone is inframe with the peptide predicted by our cDNA. Thus, the 5' UTR depicted in figure 1 may be translated. Functionally, our fibroblast expression studies clearly demonstrate both that our cDNA encodes a functional sterol Δ^7 -reductase and that the potential initiation codon that we have identified functions in human fibroblasts. Determination of the actual initiation codon will require analysis of coupled transcription-translation products and of the native protein. The predicted protein sequence is highly homologous to other sterol reductases. The highest homology was found with the A. thaliana sterol Δ^7 -reductase. In addition, like the plant sterol Δ^7 -reductase, the human enzyme does not encode an EFGGXXG motif that is found in other members of the sterol reductase family.

Cells acquire the cholesterol that they need either from dietary cholesterol or by endogenous biosynthesis of cholesterol. This is a tightly regulated process. If exogenous LDL cholesterol is available, endogenous biosynthesis of cholesterol is down-regulated. Using northern blot analysis, we looked at the expression levels of the mRNA encoding the human sterol Δ^7 -reductase from cells grown with and without an exogenous source of cholesterol. As we expected, the mRNA encoding this enzyme was up-regulated when fibroblasts were grown



Figure 4 134-bp insertion in A2SLO. *A*, Nucleotide sequence and predicted amino acid sequence of the mutant allele. The normal nucleotide sequence is in uppercase letters, and the inserted sequence is in lowercase letters. Aberrant amino acids are in lowercase letters. *B*, Northern blot analysis of sterol Δ^7 -reductase transcript from control and SLOS fibroblasts. The transcript from the A2SLO cell line is slightly larger. C, Ethidium bromide–stained gel of PCR products from control (lanes 1 and 2), A2SLO, and B3SLO cell lines. The expected 605-bp product was found in the control and B3SLO cell lines. A single aberrant 739-bp fragment was found in the A2SLO sample.

in cholesterol-deficient media. To prove functionally that this cDNA encodes an enzyme with sterol Δ^7 -reductase activity, we expressed this cDNA in SLOS fibroblasts. Stable expression of this cDNA resulted in a significant reduction in 7-DHC levels. Thus, on the basis of both homology and function, we have identified a human sterol Δ^7 -reductase.

Using radiation-hybrid mapping, we have established that the human sterol Δ^7 -reductase maps to chromosome 11q12-13. Previously, it had been reported that SLOS syndrome maps to chromosome 7q32.1 (Alley et al. 1995). This was based on the finding of a similar translocation in one biochemically confirmed case of SLOS and one historical case of SLOS (Curry et al. 1987). A second historical case of SLOS had a chromosomal translocation involving chromosome 7q34 (Berry et al. 1989). Further analysis of the breakpoint region showed that the disrupted region encodes a metabotropic glutamate receptor (Scherer et al. 1997). Thus, for a chromosomal translocation in that region to cause an autosomal recessive disorder such as SLOS, one must propose both a long-range effect on the expression of one allele and an independent mutation in the second allele. We propose that these previous reports represent an unrelated coincidence of similar chromosomal translocations in SLOS patients. Alternatively, locus heterogeneity could exist for this disorder.

To establish that mutations in the human sterol Δ^7 reductase gene cause SLOS, we sequenced cDNA clones from three unrelated SLOS type II patients. We have identified four different mutant alleles from these patients (table 2). Because SLOS is an autosomal recessive disorder, the identification of mutations in both alleles is necessary for establishing that mutations in this gene cause SLOS. In B3SLO we have identified mutations in both alleles. One is a deletion of 96 nucleotides, and the second is a single cytosine insertion between nucleotides 505 and 506. This 96-nucleotide deletion has not been observed in cDNA clones either from control cells or from other SLOS cell lines. Thus, this deletion is unlikely to represent a normal splice variant. In A2SLO, we identified a 134-bp insertion. Using sequence analysis, RT-PCR, and northern blot analysis, we could not detect a second allele. Thus, A2SLO may be homozygous for this mutation. A fourth mutant allele was identified in a third patient (C4SLO). This mutant allele has a single thymidine insertion between nucleotides 586 and 587. The SLOS mutant alleles reported in this paper all come from severely affected patients and are predicted to result in a severe disruption of the sterol Δ^7 -reductase. Although further genotype/phenotype correlation is necessary, this may explain the severe phenotype seen in these patients. It is possible that milder cases of SLOS are due to mutations in another gene. However, we propose that mutations that do not preclude translation of the highly

conserved carboxyl half of this enzyme—mutations such as missense changes—may cause milder cases of SLOS.

The data presented here demonstrate that we have cloned a cDNA encoding the human sterol Δ^7 -reductase. This conclusion is based on significant homology to an *A. thaliana* sterol Δ^7 -reductase, induction of the mRNAencoding enzyme by growth in cholesterol-deficient media, and functional correction of the biochemical defect in SLOS fibroblasts transfected with this cDNA. Furthermore, we have identified four different mutations in this gene in three unrelated SLOS patients. In one of these patients we have identified two mutant alleles, and a second patient may be homozygous for the identified mutation. Thus, we conclude that mutations in the human sterol- Δ^7 -reductase gene cause at least some cases of SLOS.

Acknowledgments

R.D.S. was supported in part by U.S. Public Health Service grant 5 M01 RR 00334 and by a Young Investigator Grant from the American Association of Pediatrics Section on Genetics and Birth Defects. We would like to express our thanks to Dr. Bruce Dowton and Rachel Slaugh for their help with this project. We would also like to express our appreciation to the families of the patients.

Electronic-Database Information

Accession numbers and URLs for data in this article are as follows:

- BLAST, http://www.ncbi.nlm.nih.gov/BLAST/
- GenBank, http://www.ncbi.nlm.nih.gov/Web/Genbank (for fungal sterol Δ^{14} -reductases [Y10624, S30769, S44170, and X94315], fungal sterol Δ^{24} -reductases [S64014 and A43765], carboxyl-terminal portions of human and rat β lamin receptors [L25941 and AB002466, respectively], and [AF062481])
- Online Mendelian Inheritance in Man (OMIM), http://www .ncbi.nlm.nih.gov/Omim (for SLOS [MIM 270400])
- Whitehead/MIT Center for Genome Research, http://www .genome.wi.mit.edu/cgi-bin/contig/rhmapper.pl (for radiation-hybrid mapping)

References

- Alley TL, Gray BA, Lee S-H, Scherer SW, Tsui L-C, Tint GS, Williams CA, et al (1995) Identification of a yeast artificial chromosome clone spanning a translocation breakpoint at 7q32.1 in a Smith-Lemli-Opitz syndrome patient. Am J Hum Genet 56:1411–1416
- Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ (1990) Basic local alignment search tool. J Mol Biol 215:403-410
- Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ (1997) Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 25:3389–3402

- Berry R, Wilson H, Robinson J, Sandlin C, Tyson W, Campbell J, Porreco R, et al (1989) Apparent Smith-Lemli-Opitz syndrome and Miller-Dieker syndrome in a family with segregating translocation t(7;17)(q34;p13.1). Am J Med Genet 34:358–365
- Bialer MG, Penchaszadeh VB, Kahn E, Libes R, Krigsman G, Lesser ML (1987) Female external genitalia and mullerian duct derivatives in a 46,XY infant with the Smith-Lemli-Opitz syndrome. Am J Med Genet 28:723–731
- Chiang C, Litingtung Y, Lee E, Young KE, Corden JL, Westphal H, Beachy PA (1996) Cyclopia and defective axial patterning in mice lacking sonic hedgehog gene function. Nature 383:407–413
- Cunniff C, Kratz LE, Moser A, Natowicz MR, Kelley RI (1997) Clinical and biochemical spectrum of patients with RSH/ Smith-Lemli-Opitz syndrome and abnormal cholesterol. Am J Med Genet 68:263–269
- Curry CJ, Carey JC, Holland JS, Chopra D, Fineman R, Golabi M, Sherman S, et al (1987) Smith-Lemli-Opitz syndrometype II: multiple congenital anomalies with male pseudohermaphroditism and frequent early lethality. Am J Med Genet 26:45–57
- Dehart DB, Lanoue L, Tint GS, Sulik KK (1997) Pathogenesis of malformations in a rodent model for Smith-Lemli-Opitz syndrome. Am J Med Genet 68:328–337
- Folch J, Lees M, Sloane SG (1957) A simple method for isolation and purification of total lipids from animal tissues. J Biol Chem 226:497–509
- Gorlin RJ, Cohen MM, Levin LS (eds) (1990) Syndromes of the head and neck. Vol 19 in: Oxford monograms on medical genetics. Oxford University Press, Oxford, pp 890–894
- Irons M, Elias ER, Salen G, Tint GS, Batta AK (1993) Defective cholesterol biosynthesis in Smith-Lemli-Opitz syndrome. Lancet 341:1414
- Kelley RI (1995) Diagnosis of Smith-Lemli-Opitz syndrome by gas chromatography/mass spectrometry of 7-dehydrocholesterol in plasma, amniotic fluid and cultured skin fibroblasts. Clin Chim Acta 236:45–58
- Lecain E, Chenivesse X, Spagnoli R, Pompon D (1996) Cloning by metabolic interference in yeast and enzymatic characterization of *Arabidopsis thaliana* sterol Δ 7-reductase. J Biol Chem 271:10866–10873
- Lei KJ, Gluzman Y, Pan CJ, Chou JY (1992) Immortalization

of virus-free human placental cells that express tissue-specific functions. Mol Endocrinol 6:703–712

- Lin DS, Conner WE, Walf DP, Neuringer M, Hachey DL (1993) Unique lipids of primate spermatozoa: desmosterol and docosahexaenoic acid. J Lipid Res 34:491–500
- Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:265–275
- Moebius FF, Fitzky BU, Lee JN, Paik Y-K, Glossmann H (1998) Molecular cloning and expression of the human Δ 7-sterol reductase. Proc Natl Acad Sci USA 95:1899–1902
- Natowicz MR, Evans JE (1994) Abnormal bile acids in the Smith-Lemli-Opitz syndrome. Am J Med Genet 50:364–367
- Porter JA, Ekker SC, Park W-J, von Kessler DP, Young KE, Chen C-H, Ma Y, et al (1996a) Hedgehog patterning activity: role of a lipophilic modification mediated by the carboxy-terminal autoprocessing domain. Cell 86:21–34
- Porter JA, Young KE, Beachy PA (1996b) Cholesterol modification of hedgehog signaling proteins in animal development. Science 274:255–259
- Roux C, Dupuis R, Horvath C, Talbot JN (1980) Teratogenic effect of an inhibitor of cholesterol synthesis (AY 9944) in rats: correlation with maternal cholesterolemia. J Nutr 110: 2310–2312
- Scherer SW, Soder S, Duvoisin RM, Huizenga JJ, Tsui LC (1997) The human metabotropic glutamate receptor 8 (GRM8) gene: a disproportionately large gene located at 7q31.3-q32.1. Genomics 44:232–236
- Shefer S, Salen G, Batta AK, Honda A, Tint GS, Irons M, Elias ER, et al (1995) Markedly inhibited 7-dehydrocholesterol-Δ7-reductase activity in liver microsomes from Smith-Lemli-Opitz homozygotes. J Clin Invest 96:1779–1785
- Smith D, Lemli L, Opitz J (1964) A newly recognized syndrome of multiple congenital anomalies. J Pediatr 64:210–217
- Tint GS, Irons M, Elias ER, Batta AK, Frieden R, Chen TS, Salen G (1994) Defective cholesterol biosynthesis associated with the Smith-Lemli-Opitz syndrome. N Engl J Med 330: 107–113
- Tint GS, Salen G, Batta AK, Shefer S, Irons M, Elias ER, Abuelo DN, et al (1995) Correlation of severity and outcome with plasma sterol levels in variants of the Smith-Lemli-Opitz syndrome. J Pediatr 127:82–87